ArticleRadiation oncology journal2025
Optimal radiotherapy dose and fractionation for stereotactic radiotherapy in excised brain metastases.
Article in Radiation oncology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStereotactic radiotherapy (SRT) is an important adjunctive treatment after excision of brain metastases. We investigated efficacy and safety outcomes of such treatment and the impact of radiotherapy dose fractionations in a real-world multi-center cohort. MATERIALS AND
methodsAll patients who received resection cavity SRT between 2018-2022 were identified from institutional databases of two tertiary oncology centers. Patient and treatment characteristics were summarized using descriptive statistics. Local control rate (LCR), distant brain control rate (DBCR), and overall survival (OS) were estimated. Prognostic factors were investigated using univariate/multivariate Cox regression. The incidence of radiation necrosis (RN) was reported.
resultsSixty-five cavities were analyzed. The most used SRT prescription was 30 Gy/5 fractions. One-year LCR, DBCR, and OS were 69.0%, 51.9%, and 71.0%, respectively. BED10 (biological effective dose using α/β ratio of 10) was a significant factor for improved local control on both univariate (hazard ratio [HR], 0.862; 95% confidence interval [CI], 0.787 to 0.944; p = 0.001) and multivariate analysis (HR, 0.890; 95% CI, 0.803 to 0.986; p = 0.026). Cavities prescribed BED10 ≥45 Gy had superior local control than those prescribed BED10 <45 Gy (p = 0.002). The rate of RN was 6.2%. Single-fraction treatment had higher rates of RN (p = 0.030). There was no significant difference in LCR between single-fraction and fractionated subgroups in cavities with BED10 ≥45 Gy (p = 0.542).
conclusionBED10 independently predicts LCR in resection cavity SRT. Fractionated treatment is associated with a lower risk of RN and did not appear to compromise outcomes as long as prescription BED10 ≥45 Gy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.